CellGro® Cytokines combine a

to state-of-the-art production,

quality control and documentation.

A batch-specific certificate

of analysis is sent with each

cytokine. CellGro® Cytokines

are components of our CellGro®

DC Kit-System.

The choice of your cytokine cocktail

influences the results of your

ex vivo cell culture dramatically.

CGX-DO/M-038b

CellGro® Cytokines are manufactured

under GMP conditions.

To ensure consistency of quality,

results must meet our pre-defined

specifications.

Several human recombinant

cytokines are available for the

generation of dendritic cells.

CellGro® GM-CSF. . . . . . . . . . . . . . . . . . . . . . . . 1012

rec. human Granulocyte-Macrophage

Colony Stimulating Factor

CellGro® IL-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . 1003

rec. human Interleukin-4

CellGro® TNF-alpha . . . . . . . . . . . . . . . . . . . . . . 1006

rec. human Tumor Necrosis Factor-alpha

CellGro® IL-6 . . . . . . . . . . . . . . . . . . . . . . . . . . . 1004

rec. human Interleukin-6

CellGro® IL-1 beta . . . . . . . . . . . . . . . . . . . . . . . 1011

rec. human Interleukin-1 beta

CellGro® Cytokines . . . . . . . . . . . . . . . . . . . Order No.

50µg

at -20°C to -80°C

carrier-free

Certificate of Analysis

Reconstitute in sterile PBS to a

final concentration of 100 µg/ml.

Recommended in CellGro® DC

Medium. For dilution with PBS

or base medium carrier protein

(0.1–1% albumin or 1–10%

appropriate serum) has to be

included. Failure to dilute product

according to these instructions

may result in loss of activity.

Store material at –20°C to –80°C.

Store diluted material at –20°C to

–80°C. Avoid multiple freeze /

thaw cycles.

• Motta MR, Castellani S, Rizzi S, Curti A,

Gubinelli F, Fogli M, Ferri E, Cellini C, Baccarani

M, Lemoli RM (2003) Generation of dendritic

cells from CD14+ monocytes positively selected

by immunomagnetic adsorption for multiple

myeloma patients enrolled in a clinical trial

of anti-idiotype vaccination.

British Journal of Hematology 121:240–250

• Schuler-Thurner B, Schultz E, Berger T, Weinlich

G, Ebner S, Woerl P, Bender A, Feuerstein

B, Fritsch P, Romani N, Schuler G. (2002)

Rapid induction of tumor- specific

type 1 T helper cells in metastatic

melanoma patients by vaccination with

mature, cryopreserved, peptide-loaded

monocyte-derived dendritic cells.

J Exp Med 195(10):1279–1288

• Mackensen A, Drager R, Schlesier M,

Mertelsmann R, Lindemann A (2000)

Presence of IgE antibodies to bovine

serum albumin in a patient developing

anaphylaxis after vaccination with human

peptide-pulsed dendritic cells. Cancer Immunol

Immunother 49:152–156

• Thurner B, Haendle I, Roder C, Dieckmann D,

Keikavoussi P, Jonuleit H, Bender A, Maczek C,

Schreiner D, von den Driesch P, Brocker EB,

Steinman RM, Enk A, Kampgen E, Schuler G

(1999) Vaccination with mage-3A1 peptidepulsed

mature, monocyte-derived dendritic cells

expands specific cytotoxic T cells and induces

regression of some metastases in advanced

stage IV melanoma. J Exp Med 190:1669–1678

• Dhodapkar MV, Steinman RM, Sapp M, Desai H,

Fossella C, Krasovsky J, Donahoe SM, Dunbar

PR, Cerundolo V, Nixon DF, Bhardwaj N (1999)

Rapid generation of broad T-cell immunity in

humans after a single injection of mature

dendritic cells. J Clin Invest 104:173–180